☆ 4.7 Review

N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications

BIOMEDICINE & PHARMACOTHERAPY (2023)

Related references

Note: Only part of the references are listed.
Article Oncology

METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer

Xiaofeng Xu et al.

Summary: This study found that the levels of METTL3 and its mediated m6A modification were elevated in non-small-cell lung cancer (NSCLC) cells treated with carbon-ion radiotherapy. Knockdown of METTL3 impaired cell proliferation, migration, invasion, and enhanced DNA damage repair and cell survival.

CANCER SCIENCE (2023)

Add to Collection
Review Genetics & Heredity

The Role of RNA m6A Modification in Cancer Glycolytic Reprogramming

Yuanqi Li et al.

Summary: Metabolic reprogramming, including glycolysis and the Warburg effect, plays a crucial role in cancer cell proliferation and survival. The m(6)A modification in RNA has been found to be closely associated with cancer metabolic reprogramming. Aberrant m(6)A modification is observed in various diseases, including cancer. Targeting m(6)A modification could be a promising approach for cancer therapy and prognosis evaluation, as it affects multiple aspects of RNA processing.

CURRENT GENE THERAPY (2023)

Add to Collection
Review Genetics & Heredity

Biological roles of adenine methylation in RNA

Konstantinos Boulias et al.

Summary: Boulias and Greer review the functions of N-6-methyladenosine (m(6)A) in RNA, covering its impact on RNA substrates, chromatin architecture, gene expression regulation, genome stability, as well as its roles in stem-cell differentiation, neurogenesis, and immunity.

NATURE REVIEWS GENETICS (2023)

Add to Collection
Review Immunology

N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms

Lin Chen et al.

Summary: As a type of cytoplasmic m(6)A-binding proteins, the YT521-B homology (YTH) domain-containing family proteins (YTHDFs) play extensive roles in regulating RNA destiny, including embryonic development, stem cell fate, fat metabolism, neuromodulation, cardiovascular effect, infection, immunity, and tumorigenesis. The YTHDF family mediates tumor proliferation, metastasis, metabolism, drug resistance, and immunity, and has the potential of predictive and therapeutic biomarkers.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Review Oncology

Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer

Xiang Lin et al.

Summary: In recent years, the incidence and mortality of colorectal cancer (CRC) have been increasing, necessitating the discovery of new drugs to enhance drug sensitivity and reverse drug tolerance. This study focuses on understanding the mechanisms of CRC chemoresistance and exploring the potential of traditional Chinese medicine (TCM) to restore sensitivity to chemotherapeutic drugs. The study thoroughly discusses mechanisms involved in restoring sensitivity, such as targeting traditional chemical drugs, assisting drug activation, increasing drug accumulation, improving the tumor microenvironment, relieving immunosuppression, and reversing reversible modifications. The study also examines the effects of TCM combined with anticancer drugs in reducing toxicity, increasing efficiency, inducing new forms of cell death, and effectively blocking drug resistance mechanisms. The aim is to explore the potential of TCM as a sensitizer for anti-CRC drugs, developing a natural, less toxic, and highly effective approach to overcome CRC chemoresistance.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection
Article Cell & Tissue Engineering

METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism

Li Han et al.

Summary: This study reveals that N6-methyladenosine (m6A), the most prevalent internal modification in mammalian mRNAs, is involved in many pathological processes. METTL16, a recently identified m6A methyltransferase, plays a crucial role in the survival of acute myeloid leukemia (AML) cells.

CELL STEM CELL (2023)

Add to Collection
Review Oncology

Emerging roles of m6A RNA modification in cancer therapeutic resistance

Wei-Wei Liu et al.

Summary: Marvelous advancements have been made in cancer therapies to improve clinical outcomes over the years. However, therapeutic resistance remains a major challenge, with complex mechanisms that are not fully understood. N6-methyladenosine (m6A) RNA modification, a hotspot in epigenetics, is gaining attention as a potential determinant of therapeutic resistance. This article primarily reviews the regulatory mechanisms of m6A in therapeutic resistance and discusses its clinical potential to overcome resistance and optimize cancer therapy. Additionally, existing problems in current research and prospects for future research are proposed.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2023)

Add to Collection
Article Plant Sciences

Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis

Xingkang Wu et al.

Summary: This study aimed to investigate the combined efficacy of Compound Kushen Injection (CKI)-derived combination strategies in p53-mutant CRC. The results showed that CKI combined with cisplatin (Cis) produced synergistic antitumor efficiency for p53-R273H/P309S mutant CRC cells. The combination of CKI and Cis reinforced cell death in a synergistic manner by inducing extrinsic apoptosis pathway.

JOURNAL OF ETHNOPHARMACOLOGY (2022)

Add to Collection
Article Oncology

FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner

Jiapeng Huang et al.

Summary: This study reveals the importance of m(6)A modification in papillary thyroid cancer (PTC) and demonstrates that m(6)A regulates glucose metabolism and tumor growth by modulating the expression of fat-mass and obesity-associated protein (FTO) and apolipoprotein E (APOE).

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Review Oncology

Functions, mechanisms, and therapeutic implications of METTL14 in human cancer

Qian Guan et al.

Summary: RNA modification, especially the m(6)A modification, plays a crucial role in cancer progression. METTL14, as the central component of the m(6)A methylated transferase complex, acts as both an oncogene and tumor suppressor gene, regulating tumorigenesis and development in various cancers. Abnormal m(6)A levels induced by METTL14 are associated with tumorigenesis, proliferation, metastasis, and invasion.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Review Oncology

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential

Jianwei Qu et al.

Summary: ALKBH5 is an RNA demethylase that modulates m(6)A modification and controls cell processes. It regulates gene expression by affecting multiple events in RNA metabolism and plays critical roles in various cancers.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

m6A modification: recent advances, anticancer targeted drug discovery and beyond

Li-Juan Deng et al.

Summary: Abnormal N6-methyladenosine (m6A) modification is closely related to cancer development, and finding targeted anticancer drugs is important. Traditional herbs and computer-synthesized compounds are reasonable sources for these drugs. Artificial intelligence has advantages in discovering m6A-targeting anticancer drugs.

MOLECULAR CANCER (2022)

Add to Collection
Article Biochemistry & Molecular Biology

METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis

Hui-Ning Fan et al.

Summary: Our study reveals that METTL14-mediated m(6)A modification of circORC5 suppresses the progression of gastric cancer by regulating the miR-30c-2-3p/AKT1S1 axis.

MOLECULAR CANCER (2022)

Add to Collection
Article Cell Biology

METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis

Rui Su et al.

Summary: METTL16 has dual functions as an m(6)A writer in the nucleus and a translation facilitator in the cytosol, promoting translation through direct interactions with ribosomal RNAs and eukaryotic initiation factors.

NATURE CELL BIOLOGY (2022)

Add to Collection
Article Plant Sciences

Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway

Hongpeng Jiang et al.

Summary: Baicalin can suppress the progression of T2D-induced liver tumors by regulating the METTL3/m(6)A/HKDC1 axis, indicating its potential application in prevention and treatment of T2D-induced liver cancer.

PHYTOMEDICINE (2022)

Add to Collection
Article Chemistry, Multidisciplinary

Glutathione-Bioimprinted Nanoparticles Targeting of N6-methyladenosine FTO Demethylase as a Strategy against Leukemic Stem Cells

Kunxia Cao et al.

Summary: In this study, FTO inhibitor-loaded GSH-bioimprinted nanocomposites were developed to selectively target leukemia cells, especially leukemia stem cells (LSCs), and induce cell death by disrupting intracellular redox status. Additionally, the nanocomposites increased m(6)A RNA modification levels and enhanced the efficacy of immune therapy.

SMALL (2022)

Add to Collection
Review Multidisciplinary Sciences

Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives

Sen Liu et al.

Summary: This review presents current evidence for enhancing the efficacy of chemotherapy in bladder cancer. The combination of chemotherapy with other treatments, such as targeted therapy and immunotherapy, is discussed. Studies have shown that these combination therapies can improve the response rate and survival of patients receiving chemotherapy. Additionally, potential targets and approaches that may enhance chemosensitivity are explored.

JOURNAL OF ADVANCED RESEARCH (2022)

Add to Collection
Article Oncology

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

Lin Shi et al.

Summary: The study found that METTL3 contributes to the progression and drug resistance of NSCLC by promoting AKT1 protein expression through regulating AKT1 mRNA m(6)A levels. High expression levels of METTL3 and AKT1 are related to poor patient survival in NSCLC.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Add to Collection
Article Biochemistry & Molecular Biology

p53 m6A modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis

Weiwei Ke et al.

Summary: The study found that the p53-m6A axis plays a crucial role in regulating the sensitivity of hepatocellular carcinoma to chemotherapy, highlighting the potential of targeting this axis in HCC therapy. By reducing METTL3 expression and increasing p53 expression, chemotherapy efficacy can be enhanced, providing a new insight into HCC treatment.

APOPTOSIS (2022)

Add to Collection
Article Cell Biology

METTL14-mediated N6-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma

Zhuonan Liu et al.

Summary: Our study reveals that METTL14 inhibits ITGB4 expression via m6A modification to attenuate metastasis and EMT of ccRCC cells, suggesting the METTL14/ITGB4 axis as a potential prognostic biomarker and therapeutic target for ccRCC.

CELL COMMUNICATION AND SIGNALING (2022)

Add to Collection
Review Biochemistry & Molecular Biology

FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms

Sarah Kassem Azzam et al.

Summary: This article reviews the role of fat mass and obesity-associated protein (FTO) in obesity and cancer. Studies have shown that FTO can promote adipogenesis and tumorigenesis, and is associated with susceptibility to obesity and various cancers.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection
Article Biochemistry & Molecular Biology

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Weijun Wan et al.

Summary: The study found that METTL3 can post-transcriptionally upregulate PD-L1 expression in an m(6)A-IGF2BP3-dependent manner to promote stabilization of PD-L1 mRNA. This may have important implications for new and efficient therapeutic strategies in tumor immunotherapy.

MOLECULAR CANCER (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression

Hao Liu et al.

Summary: The study reveals that MIR100HG serves as a positive regulator of EMT in CRC, sustaining cetuximab resistance and promoting invasion and metastasis. It interacts with hnRNPA2B1 to control Wnt signaling transcriptional activity via regulation of TCF7L2 mRNA stability, forming a feedback loop that may contribute to cetuximab resistance and metastasis in CRC.

MOLECULAR CANCER (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells

Jia Xiong et al.

Summary: The lactylation-driven METTL3-mediated RNA m(6)A modification plays an important role in promoting the immunosuppressive capacity of tumor-infiltrating myeloid cells (TIMs).

MOLECULAR CELL (2022)

Add to Collection
Article Biochemistry & Molecular Biology

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

Zhen Tan et al.

Summary: This study reveals that downregulation of FTO leads to increased m(6)A modifications in the 3'UTR of PDGFC, and then modulates its transcriptional level in an m(6)A-YTHDF2-dependent manner. PDGFC upregulation promotes cell growth, highlighting a potential therapeutic target for PDAC treatment and prognostic prediction.

ONCOGENE (2022)

Add to Collection
Article Oncology

The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer

Deepthi Ramesh-Kumar et al.

Summary: IGF2BP proteins recognize methylated mRNAs and promote cancer progression, playing a crucial role in the epitranscriptomic field. Recent studies have shown that noncoding substrates are essential for mediating the pro-growth features of the IGF2BP family.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection
Article Pharmacology & Pharmacy

A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities

Guoyou Xie et al.

Summary: FTO is a potential drug target critical for cancer progression, and the small-molecule inhibitor 18097 shows promise as a potential agent against breast cancer. This inhibitor reprograms the epitranscriptome of cancer cells, increases mRNA stability, and suppresses cellular lipogenesis. Animal studies confirm its significant suppression of in vivo growth and lung colonization of breast cancer cells.

ACTA PHARMACEUTICA SINICA B (2022)

Add to Collection
Review Oncology

m6A binding protein YTHDF2 in cancer

Xiaomin Chen et al.

Summary: YT521-B homology domain family member 2 (YTHDF2) is a protein that plays a role in various biological processes, including embryonic development, immune response, and tumor progression. It is involved in the proliferation, apoptosis, invasion, and migration of tumor cells, and modulates signaling pathways through m(6)A modification.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance

Jiajia Wu et al.

Summary: Precision medicine has expanded treatment options for NSCLC patients through targeted therapy based on genetic and epigenetic cues. Antibodies and inhibitors that target critical gene-mediated signaling pathways have improved patient prognosis. However, resistance due to genetic alterations poses significant challenges in the treatment of metastatic NSCLC patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Biological and pharmacological roles of m6A modifications in cancer drug resistance

Zaoqu Liu et al.

Summary: Cancer drug resistance is a major obstacle in cancer treatment, with N-6-methyladenosine (m(6)A) RNA modification playing a key role in resistance mechanisms. Changes in m(6)A modification can affect drug resistance by regulating multidrug efflux transporters, drug metabolism enzymes, DNA damage repair, and cell stemness. Small molecules targeting m(6)A regulators have shown potential in overcoming drug resistance.

MOLECULAR CANCER (2022)

Add to Collection
Review Pharmacology & Pharmacy

Targeted therapy for breast cancer: An overview of drug classes and outcomes

Aaron T. Jacobs et al.

Summary: Over the past 25 years, there has been significant growth in new therapeutic options for breast cancer, known as targeted therapies that block specific pathways to inhibit tumor growth and survival. This review examines the development and impact of targeted therapies in clinical use, summarizing clinical data and adverse effects in different breast cancer subtypes.

BIOCHEMICAL PHARMACOLOGY (2022)

Add to Collection
Article Oncology

Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis

Quan Ling et al.

Summary: This study investigates the detailed molecular mechanisms by which propofol enhances DDP-sensitivity in NSCLC cells. It identifies a novel m6A-dependent miR-486-5p/RAP1-NF-kappa B axis that is closely associated with this process.

BMC CANCER (2022)

Add to Collection
Article Biochemistry & Molecular Biology

METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner

Yun-Zhang Dai et al.

Summary: This study identified the METTL16/RAB11B-AS1 regulatory axis in HCC, which represented novel targets for HCC prognosis and treatment.

CELLULAR & MOLECULAR BIOLOGY LETTERS (2022)

Add to Collection
Article Gastroenterology & Hepatology

METTL3 Inhibits Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer

Huarong Chen et al.

Summary: This study identifies METTL3 as a potential therapeutic target for CRC immunotherapy. Silencing or inhibiting METTL3 reduces MDSC accumulation, sustains activation and proliferation of CD4(+) and CD8(+) T cells, and ultimately suppresses CRC development. Inhibition of METTL3 plus anti-PD1 treatment shows promising antitumor efficacy against CRC.

GASTROENTEROLOGY (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer

Bo Qin et al.

Summary: A series of novel fat mass and obesity-associated protein (FTO) inhibitors were synthesized in this study, and compound C6 showed the strongest inhibition of FTO. C6 also exhibited potent anti-proliferative activity and regulated cellular mechanisms, suggesting its potential as a treatment for esophageal cancer.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)

Add to Collection
Article Chemistry, Medicinal

Structure-Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors

Zeyu Liu et al.

Summary: The study found that the tricyclic benzoic acid inhibitor 13a can effectively inhibit FTO and has a strong anti-proliferative effect on AML cells. Treatment with 13a can upregulate the expression of ASB2 and RARA, reduce the expression of MYC, and improve the survival rate of AML cells. This study provides a potential strategy for using tricyclic benzoic acid inhibitors to treat AML.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection
Article Chemistry, Medicinal

Rational Design and Optimization m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents

Sarah Huff et al.

Summary: In this study, a new class of FTO inhibitors with high selectivity against m(6)A RNA demethylase and potent antiproliferative effects in different cancer models were developed through rational design and optimization.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection
Correction Immunology

Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell-mediated antitumor activity

Hao Zheng et al.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance

Hong Lin et al.

Summary: The resistance of tumor cells to therapy is a major cause of cancer recurrence and metastasis. Recent studies have shown that RNA modification and non-coding RNAs interact with each other, affecting the efficacy of cancer treatment. Understanding these mechanisms may lead to the development of new strategies to overcome therapeutic resistance in cancer.

MOLECULAR CANCER (2022)

Add to Collection
Review Biochemistry & Molecular Biology

The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer

Bin Shi et al.

Summary: This article summarizes the biological functions of METTL14 in gastrointestinal cancer, discusses its potential clinical applications, and proposes future research directions.

MOLECULAR CANCER (2022)

Add to Collection
Review Oncology

Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature

Juan Yan et al.

Summary: We report the first case of successful treatment of adverse skin reactions caused by sintilimab using traditional Chinese medicine. Early monitoring and recognition of symptoms, along with high-dose hormones combined TCM, may be helpful.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Add to Collection
Review Oncology

Role of m6A writers, erasers and readers in cancer

Zhen Fang et al.

Summary: The m6A modification plays a crucial role in cancers, influencing the biological functions of cancer cells and impacting patient prognosis.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Review Oncology

Exosome-based strategies for diagnosis and therapy of glioma cancer

Mohsen Karami Fath et al.

Summary: This review focuses on the role of exosomes in glioblastoma, highlighting their involvement in creating an immunosuppressive tumor microenvironment and their potential as therapeutic and diagnostic tools.

CANCER CELL INTERNATIONAL (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential

Zhengjun Lin et al.

Summary: This article systematically summarizes the roles and detailed molecular mechanisms of mesenchymal stem cell-derived exosomes (MSC-derived exosomes) in mediating cancer therapy resistance, providing novel insights into the clinical applications of MSC-derived exosomes in cancer management.

MOLECULAR CANCER (2022)

Add to Collection
Review Immunology

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Qing Tang et al.

Summary: PD-1 and PD-L1 play important roles in the progression of human cancers and are promising biomarkers for cancer therapy. The interaction between PD-1 and PD-L1 is a crucial mechanism by which human tumors evade the immune system. PD-1/PD-L1 immune-checkpoint inhibitors have shown promising therapeutic effects in human cancers, with combination therapy and predictive models as potential future directions.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Multidisciplinary Sciences

The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology

Xiang Lin et al.

Summary: Through network pharmacology, molecular docking, and experimental verification, this study found that Gegen Qinlian Decoction can reverse oxaliplatin resistance in colorectal cancer, increase drug sensitivity in tumor cells, reduce tumor volume, improve prognosis, and have good synergistic therapeutic effects.

HELIYON (2022)

Add to Collection
Review Biochemistry & Molecular Biology

N1-methyladenosine modification in cancer biology: Current status and future perspectives

Jiexin Li et al.

Summary: Post-transcriptional modifications, such as m1A modification, play a crucial role in regulating the behavior and function of RNAs. m1A modification, regulated by writers, erasers, and readers, is reversible and found in various types of RNA. It affects RNA processing, structure, and function, and has been shown to be involved in tumorigenesis.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2022)

Add to Collection
Article Oncology

METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma

Xiangyu Zeng et al.

Summary: This study reveals the potential role of METTL16 in the treatment of PDAC, particularly in cases with high METTL16 expression. Combining PARP inhibitors with gemcitabine may be an effective treatment strategy.

NATURE CANCER (2022)

Add to Collection
Article Medicine, Research & Experimental

RNA N6 -methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer

Brandon Tan et al.

Summary: This study reveals the essential role of the m(6)A reader YTHDC1 in promoting triple negative breast cancer (TNBC) metastasis. YTHDC1 enhances the nuclear export and expression of SMAD3 to augment the TGF-beta signaling cascade, leading to the formation of lung metastasis in TNBC.

THERANOSTICS (2022)

Add to Collection
Review Oncology

FTO in cancer: functions, molecular mechanisms, and therapeutic implications

Yangchan Li et al.

Summary: N-6-methyladenosine (m(6)A) is the most abundant internal modification in mRNA that affects RNA processing, stability, and translation. The fat mass and obesity-associated protein (FTO), discovered as the first RNA m(6)A demethylase, is frequently dysregulated and plays important roles in various types of cancers. Targeting FTO holds promising therapeutic significance via suppressing tumor growth, potentiating immunotherapy, and attenuating drug resistance.

TRENDS IN CANCER (2022)

Add to Collection
Review Biochemistry & Molecular Biology

The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer

Chao-Yue Sun et al.

Summary: RNA can undergo various chemical modifications, with m(6)A being the most abundant internal modification in eukaryotes. The m(6)A modification plays a crucial role in regulating mRNA processing and is implicated in tumorigenesis. IGF2BPs are unique RNA-binding proteins that stabilize mRNA targets through m(6)A modification and have important implications in cancer progression.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)

Add to Collection
Review Oncology

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Marilyne Labrie et al.

Summary: Normal and cancer cells utilize adaptive responses to survive environmental stresses, and this Review discusses how tumor ecosystems adapt to therapeutic stresses and how these adaptations can be exploited to overcome cancer therapy resistance.

NATURE REVIEWS CANCER (2022)

Add to Collection
Article Medicine, Research & Experimental

ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis

Hao Yu et al.

Summary: In bladder cancer, downregulation of ALKBH5 is associated with worse prognosis, and knockdown of ALKBH5 promotes cell proliferation, migration, and invasion while decreasing sensitivity to cisplatin chemotherapy. ALKBH5 inhibits bladder cancer progression and sensitizes cells to cisplatin through regulation of the m6A-dependent casein kinase 2 (CK2)α-mediated glycolysis pathway.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

Add to Collection
Article Biochemistry & Molecular Biology

m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells

Sarah Huff et al.

Summary: N-6-methyladenosine (m(6)A) is the most abundant mRNA modification that regulates gene expression and plays a key role in various diseases. The FTO inhibitor FTO-04 has been shown to effectively inhibit neurosphere formation in glioblastoma stem cells, making it a potential new lead for treating glioblastoma.

ACS CHEMICAL BIOLOGY (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Omeprazole improves chemosensitivity of gastric cancer cells by m(6)A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation

Shuitu Feng et al.

Summary: The study found that omeprazole can enhance the inhibitory effect of chemotherapy drugs on gastric cancer cells by regulating m(6)A modification and the FTO eraser, which is important for improving chemosensitivity.

BIOSCIENCE REPORTS (2021)

Add to Collection
Article Oncology

Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m6A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer

Wenjie Wei et al.

CANCER RESEARCH (2021)

Add to Collection
Review Pharmacology & Pharmacy

Anticancer drug resistance: An update and perspective

Ruth Nussinov et al.

Summary: Driver mutations play a critical role in cancer initiation and progression, with drug resistance being a common challenge in pharmacological treatment. The emergence of drug resistance can be attributed to a variety of mechanisms, such as mutations occurring in the same or different proteins, and in the same or parallel pathways. The complexity of genetic alterations and tumor microenvironment changes poses challenges in predicting drug resistance and requires further research in precision medicine.

DRUG RESISTANCE UPDATES (2021)

Add to Collection
Article Oncology

The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells

Aline Kowalski-Chauvel et al.

Summary: The study found that the overexpression of m6A RNA demethylase ALKBH5 in GBMSCs increases their resistance to radiation and promotes their invasive ability by controlling homologous recombination. Therefore, inhibiting ALKBH5 may be an effective therapeutic approach to overcome the radioresistance and invasiveness of GBMSCs.

CANCERS (2021)

Add to Collection
Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection
Review Biochemistry & Molecular Biology

METTL16, Methyltransferase-Like Protein 16: Current Insights into Structure and Function

Agnieszka Ruszkowska

Summary: METTL16 is a human RNA methyltransferase that installs m(6)A marks on U6 small nuclear RNA and SAM synthetase pre-mRNA, controlling a significant portion of m(6)A epitranscriptome by regulating SAM homeostasis. Structural studies have provided insight into the enzyme's interaction with coenzymes and substrates, while studies on vertebrate-conserved regions highlight their critical role in U6 snRNA interaction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Article Oncology

RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent

Xin Wang et al.

Summary: The study found a significant increase in global mRNA m6A methylation levels in patients with laryngeal squamous cell carcinoma (LSCC), highlighting the essential roles of RBM15 and IGF2BP3 in m6A methylation modification. This study identified a novel RNA regulatory mechanism in LSCC.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Pharmacology & Pharmacy

RNA methylation and cancer treatment

Baochen Yang et al.

Summary: RNA methylation plays a critical role in various biological processes, including cancer cell proliferation, metastasis, and immune response. RNA methylation-related proteins have become promising targets for cancer therapy.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection
Article Oncology

Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner

Peng Xiao et al.

Summary: The study identified that N-6-methyladenosine RNA demethylase FTO was significantly enriched in serum exosomes of gefitinib-resistant patients. Additionally, GR cell-derived exosomes decreased the sensitivity of recipient cells to gefitinib in an FTO-dependent manner. The FTO/YTHDF2/ABCC10 axis played a crucial role in the intercellular transmission of gefitinib resistance mediated by GR cell-derived exosomes.

MOLECULAR CANCER RESEARCH (2021)

Add to Collection
Article Multidisciplinary Sciences

RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming

Huilong Yin et al.

Summary: The study reveals that deletion of Mettl3 in myeloid cells promotes tumor growth and metastasis, as well as affecting the efficacy of PD-1 checkpoint blockade therapy.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Chemistry, Medicinal

Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells

Wenbin Xu et al.

Summary: This study demonstrated that quercetin has inhibitory effects on cervical cancer cells and acts synergistically with cisplatin, enhancing the antitumor effect of cisplatin by inhibiting proliferation, migration, and invasion, and promoting apoptosis through downregulating MMP2, ezrin, METTL3, and P-Gp expression.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection
Review Oncology

Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)

Wei Zhu et al.

Summary: N6-Methyladenosine (m6A) modification is crucial in cancer development, and VIRMA is associated with promoting oncogenic processes through various pathways including cell proliferation, migration, anti-apoptosis, and tumor growth. Furthermore, TCGA analysis reveals that VIRMA can predict patients' prognosis in certain types of cancer.

CANCER CELL INTERNATIONAL (2021)

Add to Collection
Article Cell Biology

Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance

Yi Liu et al.

Summary: Research has identified the m(6)A demethylase FTO as a key regulator in tumors, impacting immune surveillance through glycolytic metabolism regulation. Knockdown of FTO impairs tumor cell glycolytic activity, restores CD8(+) T cell function, and inhibits tumor growth. Additionally, the development of the small-molecule compound Dac51 can block FTO-mediated immune evasion and synergize with checkpoint blockade for improved tumor control.

CELL METABOLISM (2021)

Add to Collection
Review Medicine, Research & Experimental

The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biology and human diseases

Zuyao Chen et al.

Summary: YTHDF1 is a versatile and powerful reader protein of N-6-methyladenosine (m6A)-modified RNA, capable of recognizing various ligands without sequence selectivity, and regulating gene expression through different mechanisms. It plays a crucial role in tumor biology and diseases by promoting protein translation or affecting the expression of key factors in important cell signaling pathways.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Curcumin prevents obesity by targeting TRAF4-induced ubiquitylation in m6A-dependent manner

Yushi Chen et al.

Summary: The study reveals that curcumin prevents obesity by inhibiting adipogenesis through the regulation of m(6)A demethylase AlkB homolog 5 and YTHDF1-mediated TRAF4 expression.

EMBO REPORTS (2021)

Add to Collection
Article Oncology

Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation

Ziyi Zhao et al.

Summary: Berberine was found to inhibit tumor growth and stemness in colorectal cancer stem-like cells by decreasing m(6)A methylation, regulating FTO, and downregulating beta-catenin. This led to decreased cell proliferation, induced cell cycle arrest, reduced colony formation, and increased chemosensitivity, ultimately inhibiting malignant behaviors in colorectal CSCs.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway

Xiaofeng Liu et al.

Summary: In this study, Sec62 was identified as a novel chemoresistance-related target in colorectal cancer, with upregulation associated with poor patient outcomes. Sec62 was found to promote stemness in CRC cells through activating the Wnt signaling pathway. This study provides insights into potential therapeutic targets for improving treatment outcomes in colorectal cancer.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Chemistry, Medicinal

Novel Small Molecule RNA m6A Demethylase AlkBH5 Inhibitors for Treating Cancer

Ram W. Sabnis

ACS Medicinal Chemistry Letters (2021)

Add to Collection
Article Chemistry, Multidisciplinary

Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors

Simona Selberg et al.

Summary: Two new ALKBH5 inhibitors were found to significantly suppress the proliferation of leukemia cell lines, with IC50 values ranging from 1.38 to 16.5 μM. However, the effect on another leukemia cell line and glioblastoma cell line was minimal. This demonstrates the potential of ALKBH5 inhibition as a selective antiproliferative strategy for certain cancer cell types.

ACS OMEGA (2021)

Add to Collection
Article Andrology

The m6A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma

Hanfei Chen et al.

Summary: The research revealed that METTL3, through m6A methylation, enhances autophagy and chemoresistance in seminoma cells. ATG5 was identified as a potential target for METTL3-mediated autophagy promotion.

TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)

Add to Collection
Article Oncology

被撤回的出版物: LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance (Retracted article. See vol. 23, 2023)

Yu-Nan Ma et al.

Summary: LBX2-AS1 is significantly upregulated in colorectal cancer and positively correlated with aggressive disease characteristics, serving as an independent prognostic indicator. Mechanistically, LBX2-AS1 in CRC is regulated by METTL3-dependent m6A methylation and acts as a ceRNA to promote 5-fluorouracil resistance.

CANCER CELL INTERNATIONAL (2021)

Add to Collection
Article Oncology

M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu et al.

Summary: This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy. These findings suggest a new regulatory mechanism for PD-L1 involving mRNA epigenetic modification by ALKBH5, as well as a potential role for ALKBH5 in cancer immunotherapies.

CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells

Xu Dong Li et al.

Summary: The study demonstrates that JPX promotes GBM progression and TMZ chemoresistance through the FTO/PDK1 axis, revealing its key role in GBM aerobic glycolysis in an m6A-dependent manner. These findings suggest that JPX could be a potential therapeutic target for GBM chemotherapy.

CANCER SCIENCE (2021)

Add to Collection
Article Chemistry, Medicinal

ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an N6-Methyladenosine-Based Epitranscriptomic Mechanism

Xiaochuan Liu et al.

Summary: The increased expression of ATF3 protein in tamoxifen-resistant breast cancer cells is correlated with drug resistance and is regulated by the downregulation of YTHDF2. This leads to increased stability of ATF3 mRNA and subsequently enhances drug resistance. These findings suggest ATF3 and YTHDF2 as potential therapeutic targets for overcoming drug resistance in cancer cells.

CHEMICAL RESEARCH IN TOXICOLOGY (2021)

Add to Collection
Article Chemistry, Medicinal

METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes

Elena V. Moroz-Omori et al.

Summary: The METTL3 inhibitor was found to significantly reduce the levels of m(6)A methylation in mRNA across various cell lines, with effects lasting up to 6 days, while exhibiting selectivity towards other RNA methyltransferases without affecting their levels.

CHEMMEDCHEM (2021)

Add to Collection
Article Oncology

ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer

Sipei Nie et al.

Summary: In this study, it was found that ALKBH5 is upregulated in cisplatin-resistant EOC and promotes cancer cell resistance to cisplatin. The ALKBH5-HOXA10 loop activates the JAK2/STAT3 signaling pathway, leading to EOC chemoresistance. Inhibition of the expression of the ALKBH5-HOXA10 loop may be a potential strategy to overcome cisplatin resistance in EOC.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Chemistry, Medicinal

1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors

Aymeric Dolbois et al.

Summary: This study focuses on the medicinal chemistry optimization of a METTL3 hit compound, resulting in a significant potency improvement in a TR-FRET assay. The optimized compound, UZH2, shows target engagement in cells and is able to reduce the m(6)A/A level in specific cancer cell lines, indicating potential therapeutic effects.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection
Review Oncology

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy

Masashi Mikubo et al.

Summary: A minor population of cancer cells can evade cell death from chemotherapy and targeted therapy by entering a reversible slow proliferation state known as the drug tolerant persister (DTP) state. Understanding the biology of DTP cells and developing therapeutic strategies targeting this mechanism can have significant clinical implications in overcoming cancer persistence. Emerging evidence suggests that DTP cells adapt to new environments through epigenomic modification, transcriptomic regulation, flexible energy metabolism, and interactions with the tumor microenvironment.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Mining for METTL3 inhibitors to suppress cancer

Jiazhi Li et al.

Summary: The RNA methyltransferase METTL3 plays a crucial role in cancer development and progression, particularly in AML. A selective small molecule inhibitor of METTL3 has shown promising antileukemic effects in preclinical models, suggesting a potential new cancer therapy targeting METTL3.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Add to Collection
Article Integrative & Complementary Medicine

Aidi injection, a traditional Chinese medicine extract, reverses Gefitinib resistance in non-small cell lung cancer cells

Riya Biswas et al.

Summary: The study demonstrated that Aidi injection enhanced gefitinib sensitivity in three NSCLC cell lines and increased gefitinib-induced apoptosis. Analysis showed that high expression of the ABCC2 gene was associated with significantly poorer survival in lung adenocarcinoma patients. Additionally, docking studies suggested that Ginsenoside_Re in Aidi injection could potentially inhibit MRP2.

EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE (2021)

Add to Collection
Article Cell Biology

EMP3 negatively modulates breast cancer cell DNA replication, DNA damage repair, and stem-like properties

Kailing Zhou et al.

Summary: EMP3 acts as a potential tumor suppressor in breast cancer by inhibiting cell cycle progression, DNA repair, and stem-like properties, leading to enhanced sensitivity of breast cancer cells to DNA-damaging agents.

CELL DEATH & DISEASE (2021)

Add to Collection
Review Cell Biology

Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance

Yi-tian Chen et al.

Summary: The study identified NIFK-AS1 as a crucial regulator in the development of HCC, suggesting its potential as a new therapeutic target and predictor of sorafenib benefit in HCC patients. Knockdown of NIFK-AS1 inhibited proliferation, migration, and invasion of HCC cells, and increased sensitivity to sorafenib.

HUMAN CELL (2021)

Add to Collection
Article Oncology

A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma

Zhenchuan Liu et al.

Summary: The study identified a positive feedback loop involving METTL14/miR-99a-5p/TRIB2 that enhances CSC characteristics and radioresistance in ESCC. It was found that miR-99a-5p inhibits CSC persistence and radioresistance, while TRIB2 activates HDAC2 leading to epigenetic repression of p21 through the Akt/mTOR/S6K1 signaling pathway. Targeting this axis may provide potential therapeutic targets for ESCC treatment.

CLINICAL AND TRANSLATIONAL MEDICINE (2021)

Add to Collection
Review Biochemistry & Molecular Biology

The role of m6A modification in the biological functions and diseases

Xiulin Jiang et al.

Summary: This paper highlights the importance of m6A RNA modification in eukaryotic RNA, including the roles of m6A methyltransferases, demethylases, and binding proteins. It emphasizes the crucial role of m6A RNA modification in the development of human cancers and discusses its impact on the physiological and pathological progressions of hematopoietic, central nervous, and reproductive systems.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection
Article Medicine, Research & Experimental

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m(6)A signaling

Kaiju Sun et al.

Summary: The study revealed that SsD has broad anti-proliferation effects in AML by targeting FTO/m(6)A signaling pathway, increasing global m(6)A RNA methylation levels, and suppressing relevant pathways affecting AML cell proliferation.

THERANOSTICS (2021)

Add to Collection
Article Pharmacology & Pharmacy

Methylation of adenosine at the N6 position post-transcriptionally regulates hepatic P450s expression

Masataka Nakano et al.

BIOCHEMICAL PHARMACOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line

Alessio Malacrida et al.

BIOORGANIC & MEDICINAL CHEMISTRY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling

Bo Tang et al.

MOLECULAR CANCER (2020)

Add to Collection
Article Biochemistry & Molecular Biology

METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST

Xiao Yang et al.

MOLECULAR CANCER (2020)

Add to Collection
Article Chemistry, Medicinal

Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer

Rajiv K. Bedi et al.

CHEMMEDCHEM (2020)

Add to Collection
Article Biochemistry & Molecular Biology

RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy

Ziyou Lin et al.

EMBO JOURNAL (2020)

Add to Collection
Review Oncology

m6A-binding proteins: the emerging crucial performers in epigenetics

Yanchun Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Review Oncology

Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer

Qiang Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Oncology

TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple

Runa Zhang et al.

ONCOGENESIS (2020)

Add to Collection
Review Biochemistry & Molecular Biology

The potential role of RNA N6-methyladenosine in Cancer progression

Tianyi Wang et al.

MOLECULAR CANCER (2020)

Add to Collection
Article Oncology

Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion

Rui Su et al.

CANCER CELL (2020)

Add to Collection
Article Oncology

m6A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis

Jun-Ju He et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Article Chemistry, Analytical

Identification of Specific N6-Methyladenosine RNA Demethylase FTO Inhibitors by Single-Quantum-Dot-Based FRET Nanosensors

Yan Zhang et al.

ANALYTICAL CHEMISTRY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer

Xiaoxiang Chen et al.

MOLECULAR CANCER (2020)

Add to Collection
Article Biochemistry & Molecular Biology

m6A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy

Lingling Wang et al.

EMBO JOURNAL (2020)

Add to Collection
Article Multidisciplinary Sciences

ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

Na Li et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection
Article Cell Biology

METTL3 potentiates resistance to cisplatin through m6A modification of TFAP2C in seminoma

Jingchao Wei et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

Add to Collection
Review Oncology

Roles of METTL3 in cancer: mechanisms and therapeutic targeting

Chengwu Zeng et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Review Oncology

Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker

Zhengyi Wang et al.

CANCER MEDICINE (2020)

Add to Collection
Review Immunology

Colorectal Cancer Immunotherapy: Options and Strategies

Nor Adzimah Johdi et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yihan Yao et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

Add to Collection
Review Pharmacology & Pharmacy

Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification

Bowen Li et al.

DRUG RESISTANCE UPDATES (2020)

Add to Collection
Review Medicine, General & Internal

Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer

Xiao-Lin Su et al.

CHINESE MEDICAL JOURNAL (2020)

Add to Collection
Article Biochemistry & Molecular Biology

m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance

Tengfei Zhou et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection
Article Cell Biology

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Shuiping Liu et al.

CELL DEATH & DISEASE (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation

Nan Ding et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)

Add to Collection
Article Medicine, Research & Experimental

N6-methyladenosine-induced ERR. triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming

Zhuojia Chen et al.

THERANOSTICS (2020)

Add to Collection
Article Cell Biology

Discovery of Small Molecules that Activate RNA Methylation through Cooperative Binding to the METTL3-14-WTAP Complex Active Site

Simona Selberg et al.

CELL REPORTS (2019)

Add to Collection
Review Medicine, Research & Experimental

The role of m6A RNA methylation in cancer

Ting Sun et al.

BIOMEDICINE & PHARMACOTHERAPY (2019)

Add to Collection
Article Oncology

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia

Yue Huang et al.

CANCER CELL (2019)

Add to Collection
Review Biochemistry & Molecular Biology

The role of m6A RNA methylation in human cancer

Xiao-Yu Chen et al.

MOLECULAR CANCER (2019)

Add to Collection
Article Cell Biology

Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1

Shiming Peng et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection
Article Multidisciplinary Sciences

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade

Seungwon Yang et al.

NATURE COMMUNICATIONS (2019)

Add to Collection
Article Chemistry, Multidisciplinary

Resveratrol and Curcumin Improve Intestinal Mucosal Integrity and Decrease m6A RNA Methylation in the Intestine of Weaning Piglets

Zhending Gan et al.

ACS OMEGA (2019)

Add to Collection
Article Biochemistry & Molecular Biology

m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5

Yi Zhang et al.

MOLECULAR CANCER (2019)

Add to Collection
Article Biochemistry & Molecular Biology

Betaine increases mitochondrial content and improves hepatic lipid metabolism

Lifang Zhang et al.

FOOD & FUNCTION (2019)

Add to Collection
Article Oncology

Chinese Herbal Medicine Wenxia Changfu Formula Reverses Cell Adhesion-Mediated Drug Resistance via the Integrin beta 1-PI3K-AKT Pathway in Lung Cancer

YaNan Zhang et al.

JOURNAL OF CANCER (2019)

Add to Collection
Article Biochemistry & Molecular Biology

Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance

A. Visvanathan et al.

ONCOGENE (2018)

Add to Collection
Article Oncology

Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing

Weiwei Lai et al.

ONCOTARGET (2018)

Add to Collection
Article Biochemistry & Molecular Biology

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling

Rui Su et al.

CELL (2018)

Add to Collection
Article Cell Biology

Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway

Haizhou Liu et al.

CELL COMMUNICATION AND SIGNALING (2018)

Add to Collection
Article Endocrinology & Metabolism

Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA m6A-YTHDF2-dependent manner

Ruifan Wu et al.

INTERNATIONAL JOURNAL OF OBESITY (2018)

Add to Collection
Article Biochemistry & Molecular Biology

FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting -catenin through mRNA demethylation

Shun Zhou et al.

MOLECULAR CARCINOGENESIS (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal

Jing Wen et al.

MOLECULAR CELL (2018)

Add to Collection
Article Cell Biology

A dynamic N-6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

Fei Yan et al.

CELL RESEARCH (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Cancer Treatment by Using Traditional Chinese Medicine Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy

Jian-Shu Lou et al.

CURRENT MEDICINAL CHEMISTRY (2018)

Add to Collection
Review Pharmacology & Pharmacy

The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

Piyush Bugde et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2017)

Add to Collection
Article Multidisciplinary Sciences

RNA m6A methylation regulates the ultraviolet-induced DNA damage response

Yang Xiang et al.

NATURE (2017)

Add to Collection
Article Biochemistry & Molecular Biology

N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein

Nian Liu et al.

NUCLEIC ACIDS RESEARCH (2017)

Add to Collection
Article Oncology

A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation

Lily Mahapatra et al.

TRANSLATIONAL ONCOLOGY (2017)

Add to Collection
Article Medicine, Research & Experimental

Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells

Anna Lewinska et al.

THERANOSTICS (2017)

Add to Collection
Article Biochemistry & Molecular Biology

A Novel Inhibitor of the Obesity-Related Protein FTO

Yan Qiao et al.

BIOCHEMISTRY (2016)

Add to Collection
Article Oncology

RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated

Atsushi Tanabe et al.

CANCER LETTERS (2016)

Add to Collection
Article Biochemistry & Molecular Biology

Nuclear m6A Reader YTHDC1 Regulates mRNA Splicing

Wen Xiao et al.

MOLECULAR CELL (2016)

Add to Collection
Review Biochemistry & Molecular Biology

Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization

Patrick Maier et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Add to Collection
Article Chemistry, Medicinal

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

Wu He et al.

JOURNAL OF MEDICINAL CHEMISTRY (2015)

Add to Collection
Article Biochemistry & Molecular Biology

Meclofenamic acid selectively inhibits FTO demethylation of m(6)A over ALKBH5

Yue Huang et al.

NUCLEIC ACIDS RESEARCH (2015)

Add to Collection
Article Oncology

Herbal medicine Guan Chang Fu Fang enhances 5-fluorouracil cytotoxicity and affects drug-associated genes in human colorectal carcinoma cells

Chen Yu et al.

ONCOLOGY LETTERS (2015)

Add to Collection
Article Chemistry, Multidisciplinary

Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor

Baoen Chen et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)

Add to Collection
Article Integrative & Complementary Medicine

The Herb Medicine Formula Chong Lou Fu Fang Increases the Cytotoxicity of Chemotherapeutic Agents and Down-Regulates the Expression of Chemotherapeutic Agent Resistance-Related Genes in Human Gastric Cancer Cells In Vitro

Yongping Liu et al.

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2011)

Add to Collection
Article Integrative & Complementary Medicine

Pharmacological effects of serum containing Chinese medicine Bushen Huayu Jiedu compound recipe in lung cancer drug-resistance cells

Cao Yong et al.

CHINESE JOURNAL OF INTEGRATIVE MEDICINE (2008)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.